So you can take control of your prescription by pausing or canceling at any time via your portal or by simply contacting our team
Available as a fixed-dose combination of insulin glargine 100 units/mL and lixisenatide 33 mcg/mL (Soliqua 100/33)
Key benefits Why people compare it 1 40-60% greater healing outcomes versus either peptide alone 2 Simultaneous activation of early-phase (TB-500) and mid-phase (BPC-157) repair 3 Synergistic upregulation of both VEGF/EGF and actin-migration pathways 4 Dual anti-inflammatory action: NO system modulation plus cytokine reduction 5 Single-vial reconstitution eliminates dosing variability 6 Optimized 1:1 mass ratio matching published combination protocols 7 Thorough tendon, ligament, muscle, and joint repair support 8 No emergent toxicity beyond individual component profiles Deep research About BPC-157 / TB-500 Blend This blend combines two structurally and mechanistically distinct peptides: BPC-157 (a 15-amino acid pentadecapeptide, MW ~1419 Da, sequence GEPPPGKPADDAGLV) and TB-500 (a synthetic 43-amino acid replica of Thymosin Beta-4, MW ~4921 Da)
This means that if you are taking 3 IU per day then each vial will last you three days, with 1 IU left over
The peptide has not produced significant adverse effects even at doses many times higher than those used therapeutically in rodent research
In addition, carnitine can also activate glucocorticoid receptor (GR) and regulate glucocorticoid- responsive genes through this mechanism, playing a role in glucocorticoid regulation [81], and reducing glucocorticoid-induced muscle atrophy in patients with pemphigus [82]
